RxSight and Alcon enter collaboration to develop adjustable PCIOLs; $60M upfront, up to $140M milestones

RxSight, Inc.

RxSight receives $60M upfront; potential $70M feasibility milestone, $30M FDA submission milestone, $40M approval milestone.
Alcon to pay 30% royalties on net sales of collaboration products; RxSight to develop and manufacture, Alcon to commercialize globally.
Collaboration combines RxSight's light-adjustable technology with Alcon's presbyopia-correcting IOL optics for post-operative fine-tuning.
Agreement includes non-exclusive licenses; RxSight retains U.S. regulatory approvals and will supply LDD devices.
Deal could accelerate adoption of adjustable IOLs; Alcon is global eye care leader (SIX/NYSE: ALC).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.